公开(公告)号：US20210379151A1

公开(公告)日：2021-12-09

申请号：US17282514

申请日：2019-10-02

Applicant: Ming-Che Shih ,  ACADEMIA SINICA

Inventor： Patrick C.H. Hsieh ,  David Lundy

IPC: A61K38/18 ,  A61K31/704 ,  A61P35/00 ,  A61K9/00

Abstract: A method of facilitating the delivery of an agent across the blood-brain barrier (BBB) of a subject, the method involving the use of a low dose of vascular endothelial growth factor (VEGF) polypeptide. In some embodiments, the VEGF polypeptide can be given to the subject before and after administration of the agent at multiple doses.

公开(公告)号：US20180099056A1

公开(公告)日：2018-04-12

申请号：US15567931

申请日：2016-04-19

Applicant: Academia Sinica

Inventor： Patrick C.H. Hsieh ,  Yuan-Yuan Cheng

IPC: A61K48/00 ,  A61K31/713 ,  A61K45/06 ,  A61K38/17 ,  A61P9/10

CPC classification number: A61K48/005 ,  A61K31/713 ,  A61K38/1709 ,  A61K45/06 ,  A61P9/10 ,  C12N2310/531 ,  C12N2710/10343 ,  A61K2300/00

Abstract: A combination of active agents selected from a FoxM1 enhancer, an Id1 enhancer, and a JNK3 inhibitor and the uses thereof in promoting cardiomyocyte proliferation and treating heart diseases in a subject in need of the treatment.

公开(公告)号：US20180072993A1

公开(公告)日：2018-03-15

申请号：US15699011

申请日：2017-09-08

Applicant: Academia Sinica

Inventor： Patrick C.H. Hsieh ,  Desy S. Lee

IPC: C12N5/077 ,  C12Q1/68 ,  A61K35/34 ,  G01N33/50

CPC classification number: C12N5/0657 ,  A61K35/34 ,  C12N2501/50 ,  C12N2501/65 ,  C12N2502/1323 ,  C12N2502/28 ,  C12N2506/02 ,  C12Q1/6881 ,  C12Q2600/158 ,  G01N33/5061

Abstract: Methods for promoting maturation of cardiomyocytes, involving introducing a microRNA combination containing miR-125b, miR-199a, miR-221, and/or miR222, or suppression of ErbB4 in immature cardiomyocytes, which may be co-cultured with endothelial cells.

公开(公告)号：US20210275640A1

公开(公告)日：2021-09-09

申请号：US17327565

申请日：2021-05-21

Applicant: ACADEMIA SINICA

Inventor： Patrick C.H. Hsieh ,  David Lundy

IPC: A61K38/18 ,  A61K45/06 ,  A61K47/68 ,  A61K51/08

Abstract: Disclosed herein is a method of facilitating the delivery of an agent across blood-brain barrier (BBB) of a subject. The method includes administering to the subject in sequence or concomitantly, an effective amount of a growth factor selected from the group consisting of, vascular endothelial growth factor (VEGF), insulin-like growth factor I (IGF-1), IGF-II, a portion thereof and a combination thereof; and an agent that is any of a therapeutic agent or an imaging agent. The administered amount of the growth factor is capable of transiently increasing BBB permeability of the subject and thereby allowing the agent to be delivered across BBB. Also disclosed herein is a method of treating a subject suffering from a brain tumor, a brain stroke, a neuropsychiatric disorder and/or a neurodegenerative disease.

公开(公告)号：US20190275070A1

公开(公告)日：2019-09-12

申请号：US16337583

申请日：2017-09-29

Applicant: Academia Sinica

Inventor： Patrick C.H. Hsieh ,  Chen-Yun Chen ,  Yu-Che Cheng

IPC: A61K31/7105 ,  C07K16/28 ,  C12N15/113 ,  A61K9/00

Abstract: Methods for ameliorating cardiac is juries such as myocardial infarction by either enhancing the activity of a let-7 microRNA or inhibiting the activity of transformation growth factor beta receptor III (T GFBR3). Also provided herein are assay methods for detecting the level of TGFBR3, the level of a let-7 microRNA, or both in a biological sample.

公开(公告)号：US20170283493A1

公开(公告)日：2017-10-05

申请号：US15504956

申请日：2015-08-20

Applicant: Academia Sinica

Inventor： Patrick C.H. Hsieh ,  David Lundy

IPC: C07K16/22 ,  C07K16/28 ,  A61K51/08

CPC classification number: C07K16/22 ,  A61K38/1866 ,  A61K45/06 ,  A61K47/6835 ,  A61K51/08 ,  A61K2039/505 ,  C07K14/52 ,  C07K16/00 ,  C07K16/28 ,  C07K2319/00 ,  A61K2300/00

Abstract: Disclosed herein is a method of facilitating the delivery of an agent across blood-brain barrier (BBB) of a subject. The method includes administering to the subject in sequence or concomitantly, an effective amount of a growth factor selected from the group consisting of, vascular endothelial growth factor (VEGF), insulin-like growth factor I (IGF-1), IGF-II, a portion thereof and a combination thereof; and an agent that is any of a therapeutic agent or an imaging agent. The administered amount of the growth factor is capable of transiently increasing BBB permeability of the subject and thereby allowing the agent to be delivered across BBB. Also disclosed herein is a method of treating a subject suffering from a brain tumor, a brain stroke, a neuropsychiatric disorder and/or a neurodegenerative disease.